Kingsley, Australia

Gregory Brian Thomas



Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 38(Granted Patents)


Location History:

  • Perth, AU (2007)
  • Western Australia, AU (2009)
  • Kingsley, AU (2011 - 2013)

Company Filing History:


Years Active: 2007-2013

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations of Gregory Brian Thomas

Introduction

Gregory Brian Thomas is an accomplished inventor based in Kingsley, Australia. He has made significant contributions to the field of neuropharmacology, particularly through his innovative oral formulations. With a total of five patents to his name, Thomas has focused on enhancing the bioavailability of therapeutic compounds.

Latest Patents

One of his latest patents involves oral formulations of glycyl-2-methylprolyl-glutamate (G-2MePE). These formulations include microemulsions, coarse emulsions, liquid crystals, tablets, and encapsulated forms of G-2MePE, which have shown improved bioavailability compared to conventional aqueous formulations. Notably, microparticles, nanoparticles, and microemulsions exhibit significant neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke, even after the stroke has been initiated. This advancement suggests that improved oral formulations can be effectively used to treat various neurodegenerative conditions with enhanced convenience and efficacy.

Career Highlights

Throughout his career, Gregory Brian Thomas has worked with notable companies such as Neuren Pharmaceuticals Limited and Neuron Pharmaceuticals Limited. His work in these organizations has contributed to the development of innovative therapeutic solutions.

Collaborations

Some of his coworkers include Jingyuan Wen and Mike John Bickerdike, who have collaborated with him on various projects.

Conclusion

Gregory Brian Thomas is a prominent inventor whose work in oral formulations has the potential to revolutionize treatments for neurodegenerative diseases. His innovative approaches and collaborations continue to pave the way for advancements in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…